<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393027</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO14-MJR / LBT-999</org_study_id>
    <nct_id>NCT02393027</nct_id>
  </id_info>
  <brief_title>Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999</brief_title>
  <acronym>LBT 999</acronym>
  <official_title>Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic Parkinson's disease (IPD) is a degenerative disease affecting the dopaminergic
      system. Clinical symptoms of IPD commonly begin after the loss of at least 40 to 50% of
      striatal dopaminergic terminals (specially putaminal terminals).

      The Dopamine neuronal transporter (DAT) is a highly expressed protein in the membrane of
      presynaptic nigrostriatal dopaminergic terminals. The use of a DAT's radioligand in the
      initial stages of the disease would lead to an early detection of nigral cell loss.

      Currently, only one DAT's radioligand has obtained marketing authorization in France, the
      123I-FPCIT, for use in Single Photon Emission Computed Tomography (SPECT).

      Otherwise, the Positron Emission Tomography (PET), a more sensitive technology than SPECT
      with higher resolution has become for a few years the new gold standard for visual analysis
      and quantification of neurotransmission systems (including the dopaminergic system).

      A DAT tracer labelled with Carbon 11 ([11C] PE2l) have been developed and is currently used
      as a reference in various research centers.

      However, in order to enable a clinical use of this tracer (which currently can't be because
      of the too short period of Carbon 11), the unit INSERM U930 &quot;Imaging and Brain&quot; in
      collaboration with the CERRP (Center for Studies and Research on Radiopharmaceuticals)
      developed a new version of this tracer, labelled with 18-fluor: the [18F] LBT-999.

      The main goal of this study is to compare the [18F] LBT-999 uptake between a group of
      patients suffering from a Parkinsonien syndrome to a group healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enough inclusions for interpretation
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binding potential of [18F] LBT-999</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAT striatal density by estimating the LBT-999 distribution volume</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of lipophilic metabolites</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Idiopathic Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 idopathic parkinson disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 healthy controls (no parkinson disease)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F] LBT-999 PET</intervention_name>
    <arm_group_label>patients</arm_group_label>
    <arm_group_label>controls subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Criteria common to all participants:

          -  Age between 45 and 75 years old

          -  Signed informed consent

          -  Affiliated to a social security system

        Criteria for patients:

          -  idiopathic Parkinson's disease according to the UKPDSBB criteria

          -  stage 1-3 Hoen and Yahr (unilateral disease to moderate or mild bilateral disease in a
             self patient )

        Criteria for healthy volunteers:

          -  matching according to age (± 5 years)

        Exclusion Criteria:

        Criteria common to all participants:

          -  history of taking an antipsychotic or any other drug with a dopaminergic effect in the
             previous 6 months

          -  contraindications to MRI

          -  person with severe claustrophobia

          -  patient with a legal protection measure

          -  alcohol or drug abuse history (in the past 10 years)

          -  history of progressive disease that can affect the central nervous system (blood
             pressure greater than or equal to 180/100 mmHg, chronic lung disease with hypoxia,
             heart failure stage 4)

          -  all medical and surgical affection older than 3 months

          -  history of stroke

          -  history of head trauma (coma&gt; 24h)

          -  MMS&lt;24

          -  pregnancy or lactating woman without reliable contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Agid Y. Parkinson's disease: pathophysiology. Lancet. 1991 Jun 1;337(8753):1321-4. Review.</citation>
    <PMID>1674304</PMID>
  </reference>
  <reference>
    <citation>Brooks DJ, Pavese N. Imaging biomarkers in Parkinson's disease. Prog Neurobiol. 2011 Dec;95(4):614-28. doi: 10.1016/j.pneurobio.2011.08.009. Epub 2011 Aug 30. Review.</citation>
    <PMID>21896306</PMID>
  </reference>
  <reference>
    <citation>Brooks DJ. Imaging dopamine transporters in Parkinson's disease. Biomark Med. 2010 Oct;4(5):651-60. doi: 10.2217/bmm.10.86. Review.</citation>
    <PMID>20945978</PMID>
  </reference>
  <reference>
    <citation>Chalon S, Hall H, Saba W, Garreau L, Dollé F, Halldin C, Emond P, Bottlaender M, Deloye JB, Helfenbein J, Madelmont JC, Bodard S, Mincheva Z, Besnard JC, Guilloteau D. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. J Pharmacol Exp Ther. 2006 Apr;317(1):147-52. Epub 2005 Dec 9.</citation>
    <PMID>16339913</PMID>
  </reference>
  <reference>
    <citation>de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alpérovitch A, Rocca WA. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997 Jan;62(1):10-5.</citation>
    <PMID>9010393</PMID>
  </reference>
  <reference>
    <citation>Fernagut PO, Li Q, Dovero S, Chan P, Wu T, Ravenscroft P, Hill M, Chen Z, Bezard E. Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. PLoS One. 2010 Nov 22;5(11):e14053. doi: 10.1371/journal.pone.0014053.</citation>
    <PMID>21124922</PMID>
  </reference>
  <reference>
    <citation>Hsiao IT, Weng YH, Lin WY, Hsieh CJ, Wey SP, Yen TC, Kung MP, Lu CS, Lin KJ. Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients. Nucl Med Biol. 2014 Apr;41(4):322-9. doi: 10.1016/j.nucmedbio.2013.12.017. Epub 2014 Jan 10.</citation>
    <PMID>24503330</PMID>
  </reference>
  <reference>
    <citation>Sérrière S, Tauber C, Vercouillie J, Guilloteau D, Deloye JB, Garreau L, Galineau L, Chalon S. In vivo PET quantification of the dopamine transporter in rat brain with [¹⁸F]LBT-999. Nucl Med Biol. 2014 Jan;41(1):106-13. doi: 10.1016/j.nucmedbio.2013.09.007. Epub 2013 Oct 8.</citation>
    <PMID>24210285</PMID>
  </reference>
  <reference>
    <citation>Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, Bernardi G, Simonetti G, Stanzione P. The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1452-6. Epub 2005 Sep 8.</citation>
    <PMID>16151764</PMID>
  </reference>
  <reference>
    <citation>Sharma S, Moon CS, Khogali A, Haidous A, Chabenne A, Ojo C, Jelebinkov M, Kurdi Y, Ebadi M. Biomarkers in Parkinson's disease (recent update). Neurochem Int. 2013 Sep;63(3):201-29. doi: 10.1016/j.neuint.2013.06.005. Epub 2013 Jun 19. Review.</citation>
    <PMID>23791710</PMID>
  </reference>
  <reference>
    <citation>Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, Kimura H. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol. 1993 Sep;34(3):324-30.</citation>
    <PMID>8363349</PMID>
  </reference>
  <reference>
    <citation>Varrone A, Stepanov V, Nakao R, Tóth M, Gulyás B, Emond P, Deloye JB, Vercouillie J, Stabin MG, Jonsson C, Guilloteau D, Halldin C. Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates. J Nucl Med. 2011 Aug;52(8):1313-21. doi: 10.2967/jnumed.111.089953. Epub 2011 Jul 15.</citation>
    <PMID>21764797</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

